Nayan M, et al. - Researchers analyzed nine relevant studies (n=7,426) assessing the link between metformin use and kidney cancer survival outcomes via a search of Medline and EMBASE databases from inception to June 2017. They used random effects models to pool hazard ratios (HRs) for recurrence-free, progression-free, cancer-specific, and overall survival. By means of the Newcastle-Ottawa scale, the risk of bias was evaluated. Using meta-regression, they assessed heterogeneity. Overall, no statistically significant link between metformin use and any survival outcome in kidney cancer was evident in this systematic review and meta-analysis.